InsidersTradesSigma
基于 2 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
Browse the detailed record of transactions filed by Thomas Frank e, 管理人员. Director active across 3 companies, notably Orchard Therapeutics plc. In total, 10 filings have been logged. Breakdown: 3 buys · 0 sell. Total volume traded: €48k. History available since 1 April 2022. The latest transaction was filed on 27 February 2026 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 条申报中的 10 条
THOMAS FRANK E is a Dirigeant and is linked to Spero Therapeutics, Inc., Orchard Therapeutics plc and Larimar Therapeutics, Inc., where he is Director for the two companies so labeled and Director for Larimar Therapeutics, Inc. The 10 filings recorded, all included in the sample, cover the period from 2022-04-04 to 2026-03-02, with 48475 EUR of buys and 0 EUR of sells, and the stated transaction nature is Attribution.